Abstract：Objective To investigate the curative efficacy of Qianggan Capsules in the treatment of chronic hepatitis B (CHB) patients with hepatic fibrosis. Methods From July 2017 to July 2019, 100 patients with CHB admitted to Lianjiang People’s Hospital of Guangdong Province were selected as the research subjects. According to the random number table method, they were divided into control group and treatment group, with 50 cases in each group. Control group was treated with Glucurone Tablets and Compound Vitamin B Tablets, and study group was treated with Qianggan Capsules, all treated for six months. Alanine aminotransferase (ALT), total bilirubin (TBil), albumin (ALB), prothrombin time (PT), platelet derived growth factor BB (PDGF-BB), transforming growth factor β1 (TGF-β1), matrix metalloproteinase 1 (MMP-1), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) were compared between two groups. The change of constitution of traditional Chinese medicine in two groups were observed and the occurrence of adverse reactions was recorded. Results After treatment, ALT and TBil levels were lower than those before treatment, PT was shorter than that before treatment, and ALB level was higher than that before treatment (all P < 0.05). After treatment, there were no significant differences in ALT, TBil, ALB and PT between two groups (P ＞ 0.05). After treatment, PDGF-BB, TGF-β1, MMP-1 and TIMP-1 levels in control group were not significantly differences from those before treatment (P > 0.05). PDGF-BB, TGF-β1 and TIMP-1 levels in treatment group were lower than before treatment, and MMP-1 level was higher than that before treatment. After treatment, PDGF-BB, TGF-β1 and TIMP-1 levels in treatment group were lower than those in control group, and MMP-1 level was higher than those in control group (all P < 0.05). After treatment, there was no significant difference in the change of constitution between control group and that before treatment (P ＞ 0.05); there was statistical significance in the change of constitution in treatment group compared with that before treatment (P < 0.05). After treatment, there was statistically significant difference in the change of constitution between two groups (P < 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion Qianggan Capsules can improve hepatic fibrosis indexes and improved the constitution of traditional Chinese medicine in patients with CHB.
京公网安备 11010502046598号